tetrabutylammonium naphthalene-2-methanesulfonate | 575433-75-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: tetrabutylammonium naphthalene-2-methanesulfonate
• 英文别名: N,N,N-tributyl-1-butanaminium 2-naphthylmethanesulfonate；1-Butanaminium, N,N,N-tributyl-, 2-naphthalenemethanesulfonate；naphthalen-2-ylmethanesulfonate;tetrabutylazanium
• CAS: 575433-75-9
• 化学式: C₁₁H₉O₃S*C₁₆H₃₆N
• 分子量: 463.725
• InChiKey: NNVAPVJXTBBGQL-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  6.89
• 重原子数：
  32
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  65.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tetrabutylammonium naphthalene-2-methanesulfonate 在 五氯化磷 作用下， 以 二氯甲烷 为溶剂， 反应 0.42h， 以71%的产率得到2-萘甲烷磺酰氯
  参考文献：
  名称：

  2-萘基和5-苯并[B]噻吩基甲磺酰氯的新制备

  摘要：

  摘要 芳基甲基溴化物通过相转移磺化和PCl5氯化可制备富电子芳基甲基磺酰氯。

  DOI：

  10.1081/scc-120015818
• 作为产物：
  描述：

  2-(氯甲基)萘 在 sodium sulphite-heptahydrate 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 3.25h， 生成 tetrabutylammonium naphthalene-2-methanesulfonate
  参考文献：
  名称：

  Designing Anti-inflammatory Drugs from Parasitic Worms: A Synthetic Small Molecule Analogue of the Acanthocheilonema viteae Product ES-62 Prevents Development of Collagen-Induced Arthritis

  摘要：

  In spite of increasing evidence that parasitic worms may protect humans from developing allergic and autoimmune diseases and the continuing identification of defined helminth-derived immunomodulatory molecules, to date no new anti-inflammatory drugs have been developed from these organisms. We have approached this matter in a novel manner by synthesizing a library of drug-like small molecules based upon phosphorylcholine, the active moiety of the anti-inflammatory Acanthocheilonema viteae product, ES-62, which as an immunogenic protein is unsuitable for use as a drug. Following preliminary in vitro screening for inhibitory effects responses, a sulfone-containing phosphorylcholine analogue (11a) was selected for testing in collagen-induced arthritis (CIA). Testing revealed that 11a was as effective as ES-62 in protecting DBA/1 mice from developing CIA and mirrored its mechanism of action in downregulating the TLR/IL-1R transducer, MyD88. 11a is thus a novel prototype for anti-inflammatory drug development. on relevant macrophage cytokine an in vivo model of inflammation,

  DOI：

  10.1021/jm401251p

文献信息

• (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives
  申请人：——

  公开号：US20030199571A1

  公开（公告）日：2003-10-23

  Compounds of formula (I) wherein R is hydrogen, alkyl alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R 1 is bicyclyl or heterobicyclyl; are useful in the treatment and prophylaxis of conditions mediated by s-CD23 or TNF.

  式（I）中的化合物，其中R是氢，烷基烯基，炔基，芳基，杂芳基或杂环烷基；R1是双环烷基或杂双环烷基；在通过s-CD23或TNF介导的疾病的治疗和预防中是有用的。
• A Novel Preparation of 2-Naphthyl and 5-Benzo[B]thienyl Methanesulfonyl Chlorides
  作者：Graham Walker、Kishore K. Rana

  DOI：10.1081/scc-120015818

  日期：2003.1.4

  Abstract Electron rich arylmethylsulfonyl chlorides can be prepared from arylmethyl bromides by phase transfer sulfonation and chlorination with PCl5.

  摘要 芳基甲基溴化物通过相转移磺化和PCl5氯化可制备富电子芳基甲基磺酰氯。
• (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates
  申请人：SmithKline Beecham p.l.c.

  公开号：US20040225006A1

  公开（公告）日：2004-11-11

  Compounds of formula (I) wherein R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R 1 is bicyclyl or heterobicyclyl; are useful in the treatment and prophylaxis of conditions mediated by s-CD23 or TNF. 1

  式(I)的化合物中，其中R为氢、烷基、烯基、炔基、芳基、杂芳基或杂环基；而R1为双环烷基或杂双环烷基；可用于治疗和预防由s-CD23或TNF.1介导的疾病。
• (HETERO)BICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES
  申请人：SmithKline Beecham plc

  公开号：EP1244616A1

  公开（公告）日：2002-10-02
• [EN] (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES<br/>[FR] NOUVEAUX COMPOSES ET PROCESSUS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2001047874A1

  公开（公告）日：2001-07-05

  Compounds of formula (I) wherein R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R1 is bicyclyl or heterobicyclyl; are useful in the treatment and prophylaxis of conditions mediated by s-CD23 or TNF.